Finance

Beta
Lists
ONCY:NASDAQ
Oncolytics Biotech Inc
$0.92
0.00%
(0.00) 1D
$0.94
+2.17% (+0.020)
Pre-market
Closed: Jul 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONCY...
Mkt. cap
118.95M
Avg. vol.
1.57M
Volume
19.51K
52-wk high
$1.51
52-wk low
$0.77
Beta
1.09
Shares outstanding
119.35M
No. of employees
29
Mkt. cap
118.95M
Avg. vol.
1.57M
Volume
19.51K
52-wk high
$1.51
52-wk low
$0.77
Beta
1.09
Shares outstanding
119.35M
No. of employees
29
News stories
From sources across the web
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc
CEO-
Employees29
Founded1998
HeadquartersCalgary, Alberta, Canada
SectorBiotechnology
Websiteoncolyticsbiotech.com
Analyst ratings
Based on 4 analysts giving stock ratings to ONCY in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ONCY in the last 3 months.
Highest
Current $0.92
$10.00 (+986.96%)
Average
$6.00 (+552.17%)
Lowest
$3.00 (+226.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Boris Peaker
JonesTrading
Hold
Maintained
-
-
06/18/2026
Chad Messer
Lake Street
Buy
Maintained
$5.00
+443.5%
06/01/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$10.00
+987%
05/29/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
$3.00
+226.1%
05/21/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
04/06/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
2.81M
7.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
2.90M
6.32M
Operating expense
-
-
5.71M
13.84M
Total operating expenses
-
-
5.71M
13.84M
Operating income
-
-
-5.71M
-13.84M
Other non operating income
-
-
-196.00K
-1.05M
EBT including unusual items
-
-
-6.08M
-14.65M
EBT excluding unusual items
-
-
-6.08M
-14.65M
Income tax expense
-
-
85.00K
-252.00K
Effective tax rate
-
-
-1.40%
1.72%
Other operating expenses
-
-
-
-
Net income
-
-
-6.16M
-14.40M
Net profit margin
-
-
-
-
Earnings per share
-0.10
-0.08
-0.07
-0.14
Interest and investment income
-
-
104.00K
100.00K
Interest expense
-
-
-
-
Net interest expenses
-
-
104.00K
100.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-5.68M
-13.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer